Literature DB >> 8194193

Oncogene-induced basement membrane invasiveness in human mammary epithelial cells.

E W Thompson1, J Torri, M Sabol, C L Sommers, S Byers, E M Valverius, G R Martin, M E Lippman, M R Stampfer, R B Dickson.   

Abstract

Expression of the intermediate filament protein vimentin, and loss of the cellular adhesion protein uvomorulin (E-cadherin) have been associated with increased invasiveness of established human breast cancer cell lines in vitro and in vivo. In the current study, we have further examined these relationships in oncogenically transformed human mammary epithelial cells. A normal human mammary epithelial strain, termed 184, was previously immortalized with benzo[a]pyrene, and two distinct sublines were derived (A1N4 and 184B5). These sublines were infected with retroviral vectors containing a single or two oncogenes of the nuclear, cytoplasmic, and plasma membrane-associated type (v-rasH, v-rasKi, v-mos, SV40T and c-myc). All infectants have been previously shown to exhibit some aspects of phenotypic transformation. In the current study, cellular invasiveness was determined in vitro using Matrigel, a reconstituted basement membrane extract. Lineage-specific differences were observed with respect to low constitutive invasiveness and invasive changes after infection with ras, despite similar ras-induced transformation of each line. Major effects on cellular invasiveness were observed after infection of the cells with two different oncogenes (v-rasH + SV40T and v-rasH + v-mos). In contrast, the effects of single oncogenes were only modest or negligible. All oncogenic infectants demonstrated increased attachment to laminin, but altered secretion of the 72 kDa and 92 kDa gelatinases was not associated with any aspect of malignant progression. Each of the two highly invasive double oncogene transformants were vimentin-positive and uvomorulin-negative, a phenotype indicative of the epithelial-mesenchymal transition (EMT) previously associated with invasiveness of established human breast cancer cell lines. Weakly invasive untransformed mammary epithelial cells in this study were positive for both vimentin and uvomorulin, suggesting that uvomorulin may over-ride the otherwise vimentin-associated invasiveness.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8194193     DOI: 10.1007/bf01753886

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  62 in total

1.  Oncogenic potential of erbB-2 in human mammary epithelial cells.

Authors:  J H Pierce; P Arnstein; E DiMarco; J Artrip; M H Kraus; F Lonardo; P P Di Fiore; S A Aaronson
Journal:  Oncogene       Date:  1991-07       Impact factor: 9.867

2.  Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression.

Authors:  A D'Errico; S Garbisa; L A Liotta; V Castronovo; W G Stetler-Stevenson; W F Grigioni
Journal:  Mod Pathol       Date:  1991-03       Impact factor: 7.842

3.  Expression of type IV collagenase and procollagen genes and its correlation with the tumorigenic, invasive, and metastatic abilities of oncogene-transformed human bronchial epithelial cells.

Authors:  H Ura; R D Bonfil; R Reich; R Reddel; A Pfeifer; C C Harris; A J Klein-Szanto
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

4.  H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen.

Authors:  I E Collier; S M Wilhelm; A Z Eisen; B L Marmer; G A Grant; J L Seltzer; A Kronberger; C S He; E A Bauer; G I Goldberg
Journal:  J Biol Chem       Date:  1988-05-15       Impact factor: 5.157

5.  Stromal influences on transformation of human mammary epithelial cells overexpressing c-myc and SV40T.

Authors:  E M Valverius; F Ciardiello; N E Heldin; B Blondel; G Merlo; G Smith; M R Stampfer; M E Lippman; R B Dickson; D S Salomon
Journal:  J Cell Physiol       Date:  1990-11       Impact factor: 6.384

6.  Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with a recombinant retrovirus.

Authors:  J Bartek; J Bartkova; N Kyprianou; E N Lalani; Z Staskova; M Shearer; S Chang; J Taylor-Papadimitriou
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

7.  Rabbit antiserum against a purified surface glycoprotein decompacts mouse preimplantation embryos and reacts with specific adult tissues.

Authors:  D Vestweber; R Kemler
Journal:  Exp Cell Res       Date:  1984-05       Impact factor: 3.905

8.  Expression of activated gelatinase in human invasive breast carcinoma.

Authors:  P D Brown; R E Bloxidge; E Anderson; A Howell
Journal:  Clin Exp Metastasis       Date:  1993-03       Impact factor: 5.150

9.  Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines.

Authors:  E W Thompson; S Paik; N Brünner; C L Sommers; G Zugmaier; R Clarke; T B Shima; J Torri; S Donahue; M E Lippman
Journal:  J Cell Physiol       Date:  1992-03       Impact factor: 6.384

10.  Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-based in vitro assays.

Authors:  S N Bae; G Arand; H Azzam; P Pavasant; J Torri; T L Frandsen; E W Thompson
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more
  37 in total

1.  MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits.

Authors:  A M Tester; N Ruangpanit; R L Anderson; E W Thompson
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 2.  Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer.

Authors:  Tony Blick; Honor Hugo; Edwin Widodo; Mark Waltham; Cletus Pinto; Sendurai A Mani; Robert A Weinberg; Richard M Neve; Marc E Lenburg; Erik W Thompson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-06-04       Impact factor: 2.673

Review 3.  Mitochondrial ROS and cancer drug resistance: Implications for therapy.

Authors:  Imoh S Okon; Ming-Hui Zou
Journal:  Pharmacol Res       Date:  2015-08-11       Impact factor: 7.658

Review 4.  Biomarkers for epithelial-mesenchymal transitions.

Authors:  Michael Zeisberg; Eric G Neilson
Journal:  J Clin Invest       Date:  2009-06-01       Impact factor: 14.808

Review 5.  Tissue architecture: the ultimate regulator of epithelial function?

Authors:  C Hagios; A Lochter; M J Bissell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1998-06-29       Impact factor: 6.237

Review 6.  Intermediate filaments in the nervous system: implications in cancer.

Authors:  C L Ho; R K Liem
Journal:  Cancer Metastasis Rev       Date:  1996-12       Impact factor: 9.264

7.  Slug contributes to gemcitabine resistance through epithelial-mesenchymal transition in CD133(+) pancreatic cancer cells.

Authors:  Koichiro Tsukasa; Qiang Ding; Makoto Yoshimitsu; Yumi Miyazaki; Shyuichiro Matsubara; Sonshin Takao
Journal:  Hum Cell       Date:  2015-05-22       Impact factor: 4.174

8.  Increased WNT6 expression in tumor cells predicts unfavorable survival in esophageal squamous cell carcinoma patients.

Authors:  Lin Zhang; Gang Yuan; Yujing Fang; Miaozhen Qiu; Jianhua Lin; Jian Sun; Dajun Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

9.  Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment.

Authors:  Lydia Livas; Sumati Hasani; Natasha Kyprianou
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

10.  Dysregulation of miR-200 family microRNAs and epithelial-mesenchymal transition markers in oral squamous cell carcinoma.

Authors:  Ganesan Arunkumar; Arunagiri Kuha Deva Magendhra Rao; Mayakannan Manikandan; Harikrishnan Prasanna Srinivasa Rao; Shanmugam Subbiah; Ramachandran Ilangovan; Avaniyapuram Kannan Murugan; Arasambattu Kannan Munirajan
Journal:  Oncol Lett       Date:  2017-10-31       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.